Shengbiao Wan

1.0k total citations
49 papers, 788 citations indexed

About

Shengbiao Wan is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Shengbiao Wan has authored 49 papers receiving a total of 788 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 14 papers in Oncology and 12 papers in Organic Chemistry. Recurrent topics in Shengbiao Wan's work include Drug Transport and Resistance Mechanisms (8 papers), Cancer therapeutics and mechanisms (7 papers) and Sphingolipid Metabolism and Signaling (7 papers). Shengbiao Wan is often cited by papers focused on Drug Transport and Resistance Mechanisms (8 papers), Cancer therapeutics and mechanisms (7 papers) and Sphingolipid Metabolism and Signaling (7 papers). Shengbiao Wan collaborates with scholars based in China, Hong Kong and Canada. Shengbiao Wan's co-authors include Tao Jiang, Tak Hang Chan, Xian‐Jun Qu, Dongdong Luo, Q. Ping Dou, Kristin R. Landis‐Piwowar, Congde Huo, Kwok‐Yin Wong, Sheng Chen and Pui‐Kin So and has published in prestigious journals such as Oncogene, Chemical Communications and International Journal of Molecular Sciences.

In The Last Decade

Shengbiao Wan

46 papers receiving 775 citations

Peers

Countries citing papers authored by Shengbiao Wan

Since Specialization

Citations

This map shows the geographic impact of Shengbiao Wan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengbiao Wan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengbiao Wan more than expected).

Fields of papers citing papers by Shengbiao Wan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengbiao Wan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengbiao Wan. The network helps show where Shengbiao Wan may publish in the future.

Co-authorship network of co-authors of Shengbiao Wan

This figure shows the co-authorship network connecting the top 25 collaborators of Shengbiao Wan. A scholar is included among the top collaborators of Shengbiao Wan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengbiao Wan. Shengbiao Wan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure-Directed Optimization of Ebselen Derivatives as Potent NDM-1 Inhibitors Reverses Meropenem Resistance 2025 ·Journal of Medicinal Chemistry ·Yan Guo, Chenyu Liu, Wandong Liu, Chen Zhang, Zhiying Liu, Shengbiao Wan, Ximing Xu, Sheng Chen, Jiazhang Qiu	0
2	Design, Synthesis, Antifungal, and Nematocidal Activities of Novel Pyrimidine Derivatives Incorporating an 1,1,2-Trifluoro-1-butene Moiety 2025 ·Russian Journal of General Chemistry ·Yanling Ren, (unknown), Tao Wang, Haiyan Wang, Shengbiao Wan, Lu Yu, Pei Li	0
3	Development of molecular Trojan horses targeting New Delhi metallo-β-lactamase-1 for the restoration of meropenem susceptibility in drug-resistant bacteria 2025 ·European Journal of Medicinal Chemistry ·Wandong Liu, Yan Guo, Chen Zhang, Chenyu Liu, Sheng Chen, Xiaoyang Li, Jiazhang Qiu, Shengbiao Wan	3
4	Inhibition of sphingosine‐1‐phosphate receptor‐2 attenuates idiopathic pulmonary fibrosis by preventing its binding to dapper1 in bronchial epithelial cells 2025 ·British Journal of Pharmacology ·Shuo Mu, (unknown), Xiaoping Wu, (unknown), Zejia Sun, (unknown), Hui Shao, Xiaonan Zhang, (unknown), Ming Yang, Ming Tan, Liang Wang, Shengbiao Wan, Shu‐Xiang Cui, Xian‐Jun Qu	0
5	An overview of sphingosine‐1‐phosphate receptor 2: Structure, biological function, and small‐molecule modulators 2024 ·Medicinal Research Reviews ·(unknown), Dongdong Luo, Yuqi Jiang, Shengbiao Wan, Xiaoyang Li	7
6	In Vivo Reversal of P-Glycoprotein-Mediated Drug Resistance in a Breast Cancer Xenograft and in Leukemia Models Using a Novel, Potent, and Nontoxic Epicatechin EC31 2023 ·International Journal of Molecular Sciences ·(unknown), Iris L. K. Wong, Hkw Law, (unknown), (unknown), (unknown), (unknown), Xingkai Wang, Tak Hang Chan, Shengbiao Wan, Larry M. C. Chow	7
7	Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease 2023 ·Bioorganic Chemistry ·Wandong Liu, Juan Wang, Suyun Wang, (unknown), Yu Hu, Xiaochun Liu, (unknown), Shengbiao Wan, Ximing Xu	9
8	Novel ProTide prodrugs of 5-fluoro-2′-deoxyuridine for the treatment of liver cancer 2023 ·European Journal of Medicinal Chemistry ·(unknown), Ting Pan, (unknown), Wenmin Yuan, Xiaochun Liu, Xian‐Jun Qu, Dongdong Luo, Shengbiao Wan, Shu‐Xiang Cui	1
9	Rational Design, Synthesis, and Biological Evaluation of Novel S1PR2 Antagonists for Reversing 5-FU-Resistance in Colorectal Cancer 2022 ·Journal of Medicinal Chemistry ·Dongdong Luo, Xiaochun Liu, (unknown), Zhikun Guo, Yan Lv, (unknown), Xiaoyan Wang, Shu‐Xiang Cui, Shengbiao Wan, Xian‐Jun Qu, Ximing Xu, Xiaoyang Li	6
10	Design, synthesis, and evaluation of JTE-013 derivatives as novel potent S1PR2 antagonists for recovering the sensitivity of colorectal cancer to 5-fluorouracil 2022 ·Bioorganic Chemistry ·Zhikun Guo, Shuai Zhang, Xiaochun Liu, (unknown), Yingzhi Zhang, Dongdong Luo, (unknown), Ximing Xu, Xian‐Jun Qu, Lin Li, Shengbiao Wan, Shu‐Xiang Cui	4
11	Synthesis and evaluation of stereoisomers of methylated catechin and epigallocatechin derivatives on modulating P-glycoprotein-mediated multidrug resistance in cancers 2021 ·European Journal of Medicinal Chemistry ·Iris L. K. Wong, (unknown), Zhen Liu, (unknown), (unknown), (unknown), Peng Li, Shengbiao Wan, Larry M. C. Chow	15
12	SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression 2020 ·Oncogene ·(unknown), Wenna Shi, Shuhua Wu, (unknown), Shiyue Sun, Dongdong Luo, Shengbiao Wan, Zhikun Guo, Wenyu Wang, Xinfeng Yu, Shu‐Xiang Cui, Xian‐Jun Qu	30
13	Increased S1P induces S1PR2 internalization to blunt the sensitivity of colorectal cancer to 5-fluorouracil via promoting intracellular uracil generation 2020 ·Acta Pharmacologica Sinica ·Yuhang Zhang, Shu‐Xiang Cui, Shengbiao Wan, (unknown), Xian‐Jun Qu	10
14	Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells 2019 ·European Journal of Medicinal Chemistry ·Dongdong Luo, (unknown), (unknown), (unknown), Jiayu Yang, Shan Liu, Wanzhou Zhao, Xian‐Jun Qu, Wengong Yu, Yuchao Gu, Shengbiao Wan	37
15	Synthesis and evaluation of novel non-covalent binding quinazoline glycoside derivatives targeting the L858R and T790M variants of EGFR 2016 ·RSC Advances ·Renshuai Zhang, Shaopeng Chen, Xiaowei Zhang, Rilei Yu, Shengbiao Wan, Meiyu Geng, Tao Jiang	7
16	Synthesis of Novel Jusbetonin Analogues and Their Cytotoxicity against Tumor Cell 2015 ·Journal of Heterocyclic Chemistry ·(unknown), (unknown), (unknown), Shengbiao Wan, Tao Jiang	4
17	Anomeric selectivity and influenza A virus inhibition study on methoxylated analogues of Pentagalloylglucose 2014 ·Carbohydrate Research ·(unknown), Wei Wang, Meiting Yang, Na Du, Shengbiao Wan, Lijuan Zhang, Tao Jiang	5
18	Total synthesis and bioactivity of the marine alkaloid pityriacitrin and some of its derivatives 2011 ·European Journal of Medicinal Chemistry ·(unknown), Xiaofei Sun, Bin Xu, Krikor Bijian, Shengbiao Wan, Guigen Li, Moulay A. Alaoui‐Jamali, Tao Jiang	33
19	Synthesis, Saccharide‐Binding and Anti‐cancer Cell Proliferation Properties of Arylboronic Acid Derivatives of Indoquinolines 2011 ·Chemical Biology & Drug Design ·(unknown), Shaoqing Yu, Shengbiao Wan, Sumei Ren, Tao Jiang	5
20	The challenge of developing green tea polyphenols as therapeutic agents 2008 ·Inflammopharmacology ·Congde Huo, Shengbiao Wan, Wai Har Lam, (unknown), (unknown), Kristin R. Landis‐Piwowar, (unknown), Q. Ping Dou, Tak Hang Chan	86

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact